WSTAM
ONCE

Wilbanks Smith & Thomas Asset Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-50
Closed -$3K – 1514
2018
Q3 		$3K Buy
+50
New +$3.42K ﹤0.01% 1364

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's ONCE Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2018, closing a stake of 50 shares — an estimated $3K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in ONCE in Q3 2018 and held it in 1 quarter. The position peaked at $3K in Q3 2018. 157 funds tracked by Wall St. Rank hold ONCE as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 50 Spark Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $3K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Spark Therapeutics, Inc. Common Stock position peaked at $3K in Q3 2018.
  • 157 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.